Eplontersen vs Nucresiran
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Transthyretin Amyloidosis with Cardiomyopathy
Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Cardiomyopathy pipeline
Eplontersen · Wainua
Marketed by AstraZeneca and partners
NCT04136171 · Phase 3 · completed
This was a large randomized, double-blind, placebo-controlled trial of 1,432 treated patients with a hard clinical primary endpoint, cardiovascular death and recurrent cardiovascular events. Eplontersen did not reduce this endpoint significantly compared with placebo, so the trial is well-designed evidence of no clear benefit rather than strong evidence of a positive effect.
Next expected readout: August 2029 · NCT05667493 (registry estimate)
Reported efficacy
Composite Outcome of Cardiovascular (CV) Mortality and Recurrent CV Clinical Events up to Week 140 (Baseline up to Week 140): CARDIO-TTRansform primary composite: rate ratio 0.89 (95% CI 0.73 to 1.09), P=0.28; no significant reduction. (missed)
Result source: NCT04136171
Nucresiran
Developed by Alnylam Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: May 2030 · NCT07052903 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Transthyretin Amyloidosis with Cardiomyopathy
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Nucresiran: no structured comparison results are available for Transthyretin Amyloidosis with Cardiomyopathy.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Transthyretin Amyloidosis with Polyneuropathy
Shared mechanism: Transthyretin (TTR) · full Transthyretin Amyloidosis with Polyneuropathy pipeline
Eplontersen · Wainua
Marketed by AstraZeneca and partners
NCT04136184 · Phase 3 · completed
This open-label Phase 3 trial randomized 168 people with hereditary transthyretin amyloid polyneuropathy 6:1 to eplontersen or inotersen, but the primary efficacy comparisons were made between the eplontersen group and an external placebo group from an earlier, separate trial (NEURO-TTR). At Week 66 eplontersen was favored on neuropathy impairment (mNIS+7, LS mean difference -24.76, 95% CI -30.96 to -18.56) and on Norfolk quality of life (-19.74, 95% CI -25.63 to -13.84), and serum TTR fell by 70.42 percentage points more at Week 65, all with p<0.0001. Because the comparison group was neither randomized nor treated within this study, and no one was blinded, these results are more open to bias than a concurrent placebo-controlled comparison.
No aligned efficacy figure on record for this race.
Nucresiran
Developed by Alnylam Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07223203 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Transthyretin Amyloidosis with Polyneuropathy
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Eplontersen: registry results are on file for Transthyretin Amyloidosis with Polyneuropathy, but their comparison mappings are not yet available.
Nucresiran: no structured comparison results are available for Transthyretin Amyloidosis with Polyneuropathy.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eplontersen's landscape · Nucresiran's landscape